Response to "What is the Current Clinical Impact of the CYP2C:TG Haplotype?"

Clin Pharmacol Ther. 2024 Feb;115(2):184. doi: 10.1002/cpt.3093. Epub 2023 Nov 16.

Pablo Zubiaur¹, J Steven Leeder^{2

3}, Francisco Abad-Santos^{1

4}, Andrea Gaedigk^{2

3}

¹ Clinical Pharmacology Department, Hospital Universitario de La Princesa, Instituto Teófilo Hernando, Universidad Autónoma de Madrid (UAM), Instituto de Investigación Sanitaria La Princesa (IP), Madrid, Spain.
² Division of Clinical Pharmacology, Toxicology and Therapeutic Innovation, Children's Mercy Research Institute (CMRI), Kansas City, Missouri, USA.
³ School of Medicine, University of Missouri-Kansas City, Kansas City, Missouri, USA.
⁴ Centro de Investigación Biomédica en Red de Enfermedades Hepáticas y Digestivas (CIBERehd), Instituto de Salud Carlos III, Madrid, Spain.

No abstract available

Publication types